Miniatura

Fitxers

s13023-025-03821-1.pdf (925.41 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2025-06-07

Llicència de publicació

cc by (c) Berenguer, Marina et al, 2025
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/222286

Predictive value of liver enzymes in long-term prognosis of hepatic Wilson disease: results from the Wilson AEEH registry

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1186/s13023-025-03821-1

Resum

Background and Aims Monitoring Wilson disease (WD) is challenging due to its variable presentation and the absence of reliable biomarkers. This study aims to assess the predictive value of liver enzymes, particularly transaminases, on long-term outcomes in patients with hepatic WD using data from the Spanish Wilson Registry. Patients and Methods We analysed data from 162 WD patients with hepatic involvement and over one year of follow-up. Patients were classified as mild (no cirrhosis) or severe (with cirrhosis) at diagnosis. An unstable pattern of transaminases was defined as recurrent AST or ALT elevations. Unfavourable outcomes included new cirrhosis, elastography progression > 2 Kpa, liver transplant, or liver-related deaths. Logistic regression models were used to evaluate the impact of various factors on disease outcome. Results Of 162 patients, 81.5% had mild disease at diagnosis. Most received chelators as first-line therapy, achieving an 81.4% one-year biochemical response. After a median follow-up of 17 years, 59% exhibited an unstable transaminase pattern, and 29% had an unfavourable outcome. Key factors associated with poor outcome included older age at diagnosis (OR = 1.03), lack of early biochemical response (OR = 0.19), advanced disease markers (platelet count, albumin), and an unstable transaminase pattern (OR = 2.92). Transaminase levels did not predict outcomes based on initial disease severity. Even patients with mild disease at diagnosis and persistently normal transaminases could experience progression over time, underscoring the need for more thorough follow-up evaluations. Conclusion While transaminases are valuable for monitoring WD, they should be used alongside other biomarkers to better predict disease progression.

Matèries

Malalties del fetge, Marcadors bioquímics

Matèries (anglès)

Liver diseases, Biochemical markers

Citació

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

BERENGUER, Marina, GARCÍA VILLARREAL, Luis, OLVEIRA, Antonio, MOLLINA PÉREZ, Esther, MORENO PLANAS, José maría, ROMERO GUTIÉRREZ, Marta, PINAZO BANDERA, José maría, MASNOU RIDAURA, Helena, IRUZUBIETA, Paula, GONZÁLEZ DIÉGUEZ, María luisa, AMPUERO, Javier, FERNÁNDEZ RAMOS, José ramón, MUÑOZ, Carolina, ARENCIBIA ALMEIDA, Ana, LORENTE, Sara, DELGADO BLANCO, Manuel, BURGOS SANTAMARÍA, Diego, PONS DELGADO, Mònica, CACHERO, Alba, HERNÁNDEZ GUERRA, Manuel, GÓMEZ CAMARERO, Judith, GIL ROJAS, Sergio, LÁZARO RÍOS, María, CARMONA SORIA, Isabel, CARRIÓN, Gemma, BONO, Ariadna, MIRALPEIX, Anna, ALONSO CASTELLANO, Pablo, MARIÑO, Zoe, Registro Wilson-Aeeh. Predictive value of liver enzymes in long-term prognosis of hepatic Wilson disease: results from the Wilson AEEH registry. _Orphanet Journal of Rare Diseases_. 2025. Vol. 20, núm. 1. [consulta: 23 de gener de 2026]. ISSN: 1750-1172. [Disponible a: https://hdl.handle.net/2445/222286]

Exportar metadades

JSON - METS

Compartir registre